ABCL ABCELLERA BIOLOGICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, ABCELLERA BIOLOGICS INC reported revenue of $4.05M (down 76.3% from a year earlier), net income of −$55.4M and diluted EPS of −$0.18; over the last four quarters revenue was $66.2M and net income −$165M; for the fiscal year ended December 2025 revenue was $75.1M, up 160.6% on the year before.

ABCL annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $75.1M, gross profit n/a, operating income −$217M, net income −$146M (margin -194.9%), EPS −$0.49
• Fiscal year ended Dec 2024: revenue $28.8M, gross profit n/a, operating income −$315M, net income −$163M (margin -564.8%), EPS −$0.55
• Fiscal year ended Dec 2023: revenue $38.0M, gross profit n/a, operating income −$237M, net income −$146M (margin -385.0%), EPS −$0.51
• Fiscal year ended Dec 2022: revenue $485M, gross profit n/a, operating income $217M, net income $159M (margin 32.7%), EPS $0.50
• Fiscal year ended Dec 2021: revenue $375M, gross profit n/a, operating income $204M, net income $153M (margin 40.9%), EPS $0.48

ABCL quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $4.05M (down 76.3% year over year), net income −$55.4M, EPS −$0.18
• Quarter ended Mar 31, 2026: revenue $8.32M (up 96.3% year over year), net income −$43.2M, EPS −$0.14
• Quarter ended Dec 31, 2025 (from the annual report): revenue $44.9M (up 788.4% year over year), net income −$8.95M, EPS −$0.03
• Quarter ended Sep 30, 2025: revenue $8.96M (up 37.6% year over year), net income −$57.1M, EPS −$0.19
• Quarter ended Jun 30, 2025: revenue $17.1M (up 133.3% year over year), net income −$34.7M, EPS −$0.12
• Quarter ended Mar 31, 2025: revenue $4.24M (down 57.5% year over year), net income −$45.6M, EPS −$0.15
• Quarter ended Dec 31, 2024 (from the annual report): revenue $5.05M (down 45.0% year over year), net income −$34.2M, EPS −$0.11
• Quarter ended Sep 30, 2024: revenue $6.51M (down 1.4% year over year), net income −$51.1M, EPS −$0.17
• Quarter ended Jun 30, 2024: revenue $7.32M (down 27.2% year over year), net income −$36.9M, EPS −$0.13
• Quarter ended Mar 31, 2024: revenue $9.95M (down 18.4% year over year), net income −$40.6M, EPS −$0.14
• Quarter ended Dec 31, 2023 (from the annual report): revenue $9.18M (down 57.4% year over year), net income −$47.2M, EPS −$0.16
• Quarter ended Sep 30, 2023: revenue $6.60M (down 93.5% year over year), net income −$28.6M, EPS −$0.10
• Quarter ended Jun 30, 2023: revenue $10.1M (down 78.1% year over year), net income −$30.5M, EPS −$0.11
• Quarter ended Mar 31, 2023: revenue $12.2M (down 96.1% year over year), net income −$40.1M, EPS −$0.14
• Quarter ended Dec 31, 2022 (from the annual report): revenue $21.5M (down 84.5% year over year), net income −$29.9M, EPS −$0.10
• Quarter ended Sep 30, 2022: revenue $101M (up 1740.6% year over year), net income $26.6M, EPS $0.08
• Quarter ended Jun 30, 2022: revenue $45.9M (up 66.1% year over year), net income −$6.79M, EPS −$0.02
• Quarter ended Mar 31, 2022: revenue $317M (up 56.2% year over year), net income $169M, EPS $0.54
• Quarter ended Dec 31, 2021 (from the annual report): revenue $139M, net income $59.9M, EPS $0.20
• Quarter ended Sep 30, 2021: revenue $5.51M, net income −$21.4M, EPS −$0.08

ABCL cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$131M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$109M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$43.9M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow $277M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow $245M, share buybacks n/a

ABCL balance sheet

• Jun 30, 2026: cash $120M, total assets $1.31B, total liabilities $412M, shareholders' equity $896M
• Mar 31, 2026: cash $77.1M, total assets $1.31B, total liabilities $369M, shareholders' equity $938M
• Dec 31, 2025: cash $129M, total assets $1.36B, total liabilities $390M, shareholders' equity $967M
• Sep 30, 2025: cash $83.2M, total assets $1.36B, total liabilities $392M, shareholders' equity $964M
• Jun 30, 2025: cash $92.4M, total assets $1.40B, total liabilities $395M, shareholders' equity $1.01B
• Mar 31, 2025: cash $159M, total assets $1.34B, total liabilities $321M, shareholders' equity $1.02B
• Dec 31, 2024: cash $156M, total assets $1.36B, total liabilities $304M, shareholders' equity $1.06B
• Sep 30, 2024: cash $127M, total assets $1.39B, total liabilities $315M, shareholders' equity $1.08B

What is ABCL's revenue?

ABCELLERA BIOLOGICS INC reported $66.2M of revenue over its last four quarters, through June 30, 2026.

Is ABCL profitable?

No. ABCELLERA BIOLOGICS INC lost $165M over the last four quarters.

What is ABCL's EPS?

Diluted earnings per share over the last four quarters were −$0.54; −$0.18 in the latest quarter.

ABCL ownership and insider trades · All stocks